IM Cannabis

Company Overview

Snapshot

Founded in January 2008, IM Cannabis operates with 11–50 employees and has raised a total of $68 million across 14 funding rounds from 2 investors. The company became public on NASDAQ in March 2021.

Business overview

IM Cannabis is an international cannabis company focused on providing premium medical cannabis products to patients in Israel and Germany, two significant medical cannabis markets. The company utilizes a transnational ecosystem, driven by a data-centric approach and a globally sourced product supply chain, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Medical Cannabis.

Strategic signal

In June 2026, IM Cannabis announced its intention to sell its European activities, a strategic move expected to significantly reduce its debt by CAD$10.5 million. This indicates a pivot towards streamlining operations and improving financial health, signaling a focus on core markets or a restructuring of its international footprint to investors.

Company Intelligence Q&A

What was IM Cannabis's most recent funding activity?

In June 2026, IM Cannabis raised US$225,000 of gross proceeds in convertible note financing.

What was a key strategic move by IM Cannabis in March 2026?

In March 2026, IM Cannabis announced a strategic entry into the cyber drone interception and satellite intelligence markets by signing a non-binding agreement to acquire a 51% stake in Blackaxe Technologies.

When did IM Cannabis report its 2025 financial results?

IM Cannabis reported its 2025 financial results on March 31, 2026, showing revenue of C$54.7 million with over 134% growth in Germany and positive operating cash flow.

What was IM Cannabis's financial performance in the first quarter of 2026?

IM Cannabis announced its first quarter 2026 financial results on May 13, 2026.

What significant corporate action did IM Cannabis announce in June 2026 regarding its European operations?

In June 2026, IM Cannabis Corp. entered into a Letter of Intent to sell its European activities, expecting to significantly reduce debt by CAD$10.5 million.